PURPOSE Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor,
demonstrated superior progression-free survival (PFS) and improved health-related quality …

Background Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, has
robust efficacy in patients with ALK-positive non–small-cell lung cancer (NSCLC) that is …

Introduction In the phase 3 study entitled ALK in Lung cancer Trial of brigAtinib in 1st Line
(ALTA-1L), which is a study of brigatinib in ALK inhibitor–naive advanced ALK-positive …

Background The efficacy of the ALK inhibitor crizotinib as compared with standard
chemotherapy as first-line treatment for advanced ALK-positive non–small-cell lung cancer …

Abstract Objectives The J-ALEX study compared the efficacy and safety of alectinib with
crizotinib in Japanese patients with advanced ALK-positive non-small-cell lung cancer …

9008 Background: ALC showed promising efficacy and tolerability in the phase I/II study (AF-
001JP). Here, we conducted the randomized open-label phase III trial (J-ALEX study …

Background Crizotinib is approved to treat advanced ALK-positive non-small-cell lung
cancer (NSCLC), but most patients ultimately develop progressive disease (PD). We …

Introduction The phase III randomized PROFILE 1014 study demonstrated superiority of
crizotinib to first-line chemotherapy in prolonging progression-free survival (PFS) in …

Simple Summary The prognosis of non-small cell lung cancer (NSCLC) is poor as more than
half of the patients are diagnosed at an advanced stage. The outcomes have greatly …

Overall survival (OS) with the anaplastic lymphoma kinase (ALK) inhibitor (ALKi) crizotinib in
a large population of unselected patients with ALK-positive non-small-cell lung cancer …